Contact information
Research groups
David Kerr
CBE FMedSci FRCP
Professor of Cancer Medicine
- Consultant Physician
Genetics and Genomics
In collaboration with Dr Rachel Midgley, Oncology Clinical Trials Office, we have conducted a series of international adjuvant trials of chemotherapy for colorectal cancer. In parallel, we have established a biorepository of tissue and constitutional DNA (n=3500) which has allowed us to collaborate with Ian Tomlinson to generate a number of cancer susceptibility SNPs and commercial partners to characterise a prognostic mRNA signature which assists in selection of patients for chemotherapy. We are currently developing biomarkers for the anti-angiogenic agent bevacizumab.
Key publications
-
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Journal article
Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557
Recent publications
-
Data from Coevolution of Atypical <i>BRAF</i> and <i>KRAS</i> Mutations in Colorectal Tumorigenesis
Other
Woolley CE. et al, (2025)
-
Figure 3 from Coevolution of Atypical <i>BRAF</i> and <i>KRAS</i> Mutations in Colorectal Tumorigenesis
Other
Woolley CE. et al, (2025)
-
Figure 4 from Coevolution of Atypical <i>BRAF</i> and <i>KRAS</i> Mutations in Colorectal Tumorigenesis
Other
Woolley CE. et al, (2025)
-
Figure 5 from Coevolution of Atypical <i>BRAF</i> and <i>KRAS</i> Mutations in Colorectal Tumorigenesis
Other
Woolley CE. et al, (2025)
-
Supplementary Data 1 from Coevolution of Atypical <i>BRAF</i> and <i>KRAS</i> Mutations in Colorectal Tumorigenesis
Other
Woolley CE. et al, (2025)